Alnylam, Regeneron to partner for RNAi treatments
Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.
from Reuters: Health News https://reut.rs/2OZdnj5
http://bit.ly/2zwRqiM